Novel High-Sensitive D-Dimer Determination Predicts Chemotherapy-Associated Venous Thromboembolism in Intermediate Risk Lung Cancer Patients

Ferroni, Patrizia; Martini, Francesca; Portarena, Ilaria; Massimiani, Gioia; Riondino, Silvia; Farina, Francesca; Mariotti, Sabrina; Roselli, Mario

doi:10.1016/j.cllc.2012.03.005

Cited by 50 publications

(46 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increased plasma levels of coagulation activation markers, D-dimer and prothrombin fragment 1 + 2 (F1 + 2), were reported to be useful in prediction of VTE development [9–12]. Thrombin-antithrombin complex (TAT) reflects hypercoagulable states directly as with F1 + 2, and plasmin α2-plasmin inhibitor complex (PIC) reflects hyperfibrinolytic states [13].…”

Section: Introductionmentioning

confidence: 99%

Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study

et al. 2017

View full text Add to dashboard Cite

BackgroundAlthough Asian population was recognized to have a lower risk of venous thromboembolism (VTE), its increasing prevalence and incidence remain unclear in patients with malignancies. We attempted to predict VTE development using activation markers of coagulation and fibrinolysis.MethodsWe enrolled patients with malignancy admitted to Tonan Hospital between April and December 2014 to receive a new-for-them chemotherapy regimen. All patients were examined for VTE by computed tomography and whole-leg compression ultrasonography before chemotherapy and three months later. We also examined plasma levels of thrombin-antithrombin complex (TAT) and plasmin α2-plasmin inhibitor complex (PIC) before chemotherapy. The cut off values of TAT and PIC were set at 2.1 ng/mL and 1.8 μg/mL, respectively.ResultsOf 97 patients, the majority (67%) had distant metastases. The most common malignancies were colorectal (26%), breast (23%), and stomach (19%) cancer. VTE was detected in 29 patients (31%); all were asymptomatic. VTE was newly developed in 12 patients in the three-month observation period, which means the incidence was 49 per 1000 person-years. Non-increased PIC with increased TAT was the only significant risk factor for both VTE prevalence and incidence in multivariate analysis, and the odds ratios were 3.0 (95% confidence interval, 1.1–8.2; P = 0.034) and 9.4 (95% confidence interval, 1.7–51.9; P = 0.011), respectively.ConclusionsThe prevalence and incidence of VTE were high in hospitalized Japanese patients receiving chemotherapy for malignancies. Non-increased PIC with increased levels of TAT may be an independent risk factor for VTE development.

show abstract

Section: Introductionmentioning

confidence: 99%

Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A close interrelation between cancer progression and activation of the coagulation system has been suggested. 39 Several studies indicate that D-dimer is associated with the risk of VTE in patients with cancer [40][41][42][43] (Table 1). Also in CATS, D-dimer was shown to be a valuable biomarker for prediction of VTE in cancer patients (Figure 1).…”

mentioning

confidence: 99%

Biomarkers for prediction of venous thromboembolism in cancer

Pabinger

Thaler

2013

Blood

217

170

View full text Add to dashboard Cite

Cancer patients are at increased risk of deep vein thrombosis and pulmonary embolism. The incidence among different groups of cancer patients varies considerably depending on clinical factors, the most important being tumor entity and stage. Biomarkers have been specifically investigated for their capacity of predicting venous thromboembolism (VTE) during the course of disease. Parameters of blood count analysis (elevated leukocyte and platelet count and decreased hemoglobin) have turned out to be useful in risk prediction. Associations between elevated levels and future VTE have been found for d-dimer, prothrombin fragment 1+2, and soluble P-selectin and also for clotting factor VIII and the thrombin generation potential. The results for tissue factor–bearing microparticles are heterogeneous: an association with occurrence of VTE in pancreatic cancer might be present, whereas in other cancer entities, such as glioblastoma, colorectal, or gastric carcinoma, this could not be confirmed. Risk assessment models were developed that include clinical and laboratory markers. In the high-risk categories, patient groups with up to a >20% VTE rate within 6 months can be identified. A further improvement in risk stratification would allow better identification of patients for primary VTE prevention using indirect or novel direct anticoagulants.

show abstract

“…In 2009, Arpaia et al [36] found that mean D-dimer values were higher in cancer patients with VTE (2,195 ± 1,382 vs. 695 ± 1,039 ng/mL, p < 0.001), and multivariate analysis showed that baseline D-dimer levels were correlated with the subsequent development of VTE. Associations between an elevated D-dimer level and an increased risk of VTE have been found in other studies on colorectal cancer [37], gynaecological cancer [38], breast cancer [39], and lung cancer [40]. However, in our study, the mean D-dimer level was lower in patients who developed VTE than in patients who did not (542.69 ± 631.86 vs. 925.26 ± 1,156.5).…”

Section: Discussionmentioning

confidence: 93%

Can Biomarkers of Coagulation, Platelet Activation, and Inflammation Predict Venous Thromboembolism in Patients with Haematological Malignancies?

et al. 2019

View full text Add to dashboard Cite

Background: The incidence of venous thromboembolism (VTE) in haematological malignancies varies according to the type and grade of the disease and clinical variables, and there is a need to develop a tool to predict the occurrence of VTE in cancer patients at diagnosis to tailor prophylactic anticoagulation use during treatment. Objective: To study the incidence of VTE in haematological malignancies and clarify whether vascular and inflammatory biomarkers could be used as predictors of VTE in those patients. Methods: This was a prospective observational cohort study. Hypercoagulability and inflammatory biomarkers were assayed in a group of 171 patients with haematological malignancies at diagnosis. These markers included (1) coagulation and fibrinolysis activation markers (D-dimer, fibrinogen, antithrombin, plasminogen activator inhibitor 1), (2) endothelial and platelet activation markers (von Willebrand factor and soluble P-selectin), and (3) inflammatory markers (tumour necrosis factor αand interleukin 6). The end point was mortality or symptomatic VTE. Results/Conclusion: The incidence of symptomatic VTE was 7%. None of the tested biomarkers showed statistical significance as predictors for the occurrence of VTE in haematological malignancies. However, there were statistically significant associations between the occurrence of VTE and central venous access device insertion, the prothrombin time, and the erythrocyte sedimentation rate. An ESR above 106.5 mm/h is associated with increased VTE occurrence.

show abstract

Novel High-Sensitive D-Dimer Determination Predicts Chemotherapy-Associated Venous Thromboembolism in Intermediate Risk Lung Cancer Patients

Cited by 50 publications

References 22 publications

Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study

Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study

Biomarkers for prediction of venous thromboembolism in cancer

Can Biomarkers of Coagulation, Platelet Activation, and Inflammation Predict Venous Thromboembolism in Patients with Haematological Malignancies?

Contact Info

Product

Resources

About